Eupraxia Pharmaceuticals Statistics
Total Valuation
EPRX has a market cap or net worth of $113.99 million. The enterprise value is $104.47 million.
Important Dates
The next estimated earnings date is Friday, February 7, 2025, after market close.
| Earnings Date | Feb 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
EPRX has 35.62 million shares outstanding. The number of shares has increased by 40.29% in one year.
| Current Share Class | 35.62M |
| Shares Outstanding | 35.62M |
| Shares Change (YoY) | +40.29% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 25.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 11.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.17, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.17 |
| Quick Ratio | 3.70 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -36.63 |
Financial Efficiency
Return on equity (ROE) is -301.58% and return on invested capital (ROIC) is -128.67%.
| Return on Equity (ROE) | -301.58% |
| Return on Assets (ROA) | -110.11% |
| Return on Capital (ROIC) | -128.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$973,123 |
| Employee Count | 29 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, EPRX has paid $36,423 in taxes.
| Income Tax | 36,423 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.31% in the last 52 weeks. The beta is 1.23, so EPRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | -16.31% |
| 50-Day Moving Average | 3.17 |
| 200-Day Moving Average | 2.81 |
| Relative Strength Index (RSI) | 53.17 |
| Average Volume (20 Days) | 6,604 |
Short Selling Information
The latest short interest is 128,474, so 0.36% of the outstanding shares have been sold short.
| Short Interest | 128,474 |
| Short Previous Month | 44,831 |
| Short % of Shares Out | 0.36% |
| Short % of Float | 0.50% |
| Short Ratio (days to cover) | 20.81 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -31.50M |
| Pretax Income | -23.08M |
| Net Income | -28.22M |
| EBITDA | -31.40M |
| EBIT | -31.50M |
| Earnings Per Share (EPS) | -$0.89 |
Full Income StatementBalance Sheet
The company has $8.66 million in cash and $93,049 in debt, giving a net cash position of $8.57 million or $0.24 per share.
| Cash & Cash Equivalents | 8.66M |
| Total Debt | 93,049 |
| Net Cash | 8.57M |
| Net Cash Per Share | $0.24 |
| Equity (Book Value) | 7.98M |
| Book Value Per Share | 0.27 |
| Working Capital | 7.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$29.92 million and capital expenditures -$109,297, giving a free cash flow of -$30.03 million.
| Operating Cash Flow | -29.92M |
| Capital Expenditures | -109,297 |
| Free Cash Flow | -30.03M |
| FCF Per Share | -$0.84 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |